Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@jax.org
Gene | FGFR3 |
Variant | R248C |
Impact List | missense |
Protein Effect | gain of function |
Gene Variant Descriptions | FGFR3 R248C lies within the extracellular domain of the Fgfr3 protein (UniProt.org). R248C confers a gain of function to the Fgfr3 protein as demonstrated by constitutive ligand-independent cell proliferation (PMID: 19381019) and increased activation of the Mapk signaling pathway (PMID: 24626198). |
Associated Drug Resistance | |
Category Variants Paths |
FGFR3 mutant FGFR3 act mut FGFR3 R248C |
Transcript | NM_000142.4 |
gDNA | chr4:g.1801837C>T |
cDNA | c.742C>T |
Protein | p.R248C |
Source Database | RefSeq |
Genome Build | GRCh38/hg38 |
Transcript | gDNA | cDNA | Protein | Source Database | Genome Build |
---|---|---|---|---|---|
XM_006713868.1 | chr4:g.1801837C>T | c.742C>T | p.R248C | RefSeq | GRCh38/hg38 |
NM_001163213 | chr4:g.1801837C>T | c.742C>T | p.R248C | RefSeq | GRCh38/hg38 |
XM_006713869.1 | chr4:g.1801837C>T | c.742C>T | p.R248C | RefSeq | GRCh38/hg38 |
XM_011513420 | chr4:g.1801837C>T | c.742C>T | p.R248C | RefSeq | GRCh38/hg38 |
XM_006713871 | chr4:g.1801837C>T | c.742C>T | p.R248C | RefSeq | GRCh38/hg38 |
XM_006713871.1 | chr4:g.1801837C>T | c.742C>T | p.R248C | RefSeq | GRCh38/hg38 |
XM_006713873 | chr4:g.1801837C>T | c.742C>T | p.R248C | RefSeq | GRCh38/hg38 |
NM_001354810.1 | chr4:g.1801837C>T | c.742C>T | p.R248C | RefSeq | GRCh38/hg38 |
XM_006713868 | chr4:g.1801837C>T | c.742C>T | p.R248C | RefSeq | GRCh38/hg38 |
NM_022965 | chr4:g.1801837C>T | c.742C>T | p.R248C | RefSeq | GRCh38/hg38 |
XM_011513422 | chr4:g.1801837C>T | c.742C>T | p.R248C | RefSeq | GRCh38/hg38 |
NM_000142.4 | chr4:g.1801837C>T | c.742C>T | p.R248C | RefSeq | GRCh38/hg38 |
NM_001354809.1 | chr4:g.1801837C>T | c.742C>T | p.R248C | RefSeq | GRCh38/hg38 |
XM_006713870 | chr4:g.1801837C>T | c.742C>T | p.R248C | RefSeq | GRCh38/hg38 |
XM_006713872 | chr4:g.1801837C>T | c.742C>T | p.R248C | RefSeq | GRCh38/hg38 |
NM_001163213.1 | chr4:g.1801837C>T | c.742C>T | p.R248C | RefSeq | GRCh38/hg38 |
XM_011513420.1 | chr4:g.1801837C>T | c.742C>T | p.R248C | RefSeq | GRCh38/hg38 |
XM_006713869 | chr4:g.1801837C>T | c.742C>T | p.R248C | RefSeq | GRCh38/hg38 |
NM_000142 | chr4:g.1801837C>T | c.742C>T | p.R248C | RefSeq | GRCh38/hg38 |
XM_011513422.1 | chr4:g.1801837C>T | c.742C>T | p.R248C | RefSeq | GRCh38/hg38 |
XM_006713873.1 | chr4:g.1801837C>T | c.742C>T | p.R248C | RefSeq | GRCh38/hg38 |
NM_022965.3 | chr4:g.1801837C>T | c.742C>T | p.R248C | RefSeq | GRCh38/hg38 |
XM_006713870.1 | chr4:g.1801837C>T | c.742C>T | p.R248C | RefSeq | GRCh38/hg38 |
Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
---|---|---|---|---|---|---|
NCT04917809 | Phase II | Erdafitinib | A Study of Erdafitinib in People With Recurrent Non-Invasive Bladder Cancer | Recruiting | USA | 0 |
NCT05564416 | Phase II | Erdafitinib Atezolizumab + Erdafitinib | Testing Anti-Cancer Drugs Erdafitinib With or Without Atezolizumab in Patients With Localized Bladder Cancer Not Able to Receive Cisplatin Chemotherapy, NERA Trial | Recruiting | CAN | 0 |
NCT04972253 | Phase I | Infigratinib | Phase I BLASST-3 Trial ((BLASST)-3) | Withdrawn | 0 |